BiotechTube
Vaccizone

Vaccizone

London, Europe - Other· Est.
vaccizone.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.7M

Overview

Vaccizone is a private, pre-clinical stage biotech founded in 2020 and headquartered in London, with significant R&D operations in Istanbul. The company's proprietary ASC technology platform utilizes a modified inflammasome complex (ASC speck) to deliver antigens, offering improved stability, enhanced delivery to antigen-presenting cells, and intrinsic adjuvant properties. Its initial pipeline includes programs for COVID-19, melanoma, and veterinary vaccines, positioning it to address significant unmet needs in vaccine development and immunotherapy.

Infectious DiseaseOncologyVeterinary Health

Technology Platform

Patented ASC (Apoptosis-associated Speck-like protein) technology, a modified inflammasome complex used as a delivery platform to enhance antigen stability, delivery to immune cells, and provide intrinsic adjuvant activity.

Funding History

2
Total raised:$3.7M
Grant$1.2M
Seed$2.5M

Opportunities

The ASC platform's thermostability addresses a major global challenge in vaccine logistics, offering a potential cost and distribution advantage, especially in emerging markets.
The technology's applicability across human infectious disease, oncology, and animal health creates multiple shots on goal for value creation and partnership opportunities.

Risk Factors

The company faces significant technical risk in translating promising platform features into safe and effective human vaccines.
As a pre-revenue, early-stage private company, it carries substantial funding and execution risk in a highly competitive vaccine technology landscape.

Competitive Landscape

Vaccizone competes in a crowded field of novel vaccine platforms, including mRNA (Moderna, BioNTech), viral vectors (AstraZeneca, J&J), and other adjuvant/delivery systems. Its differentiation hinges on proving superior stability and a unique mechanism of action combining delivery and adjuvant effects in one complex.

More companies in Drug Delivery & Formulation →More companies in Europe - Other →